These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32802609)

  • 41. Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding.
    Cohen AT; Lewis M; Connor A; Connolly SJ; Yue P; Curnutte J; Alikhan R; MacCallum P; Tan J; Green L
    J Am Coll Emerg Physicians Open; 2022 Apr; 3(2):e12655. PubMed ID: 35280921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status of oral anticoagulant reversal strategies: a review.
    Rawal A; Ardeshna D; Minhas S; Cave B; Ibeguogu U; Khouzam R
    Ann Transl Med; 2019 Sep; 7(17):411. PubMed ID: 31660310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Difficulties Detecting Clinically Relevant Factor Xa Inhibitor Levels Prior to Reversal With Andexanet Alfa for Intracranial Hemorrhage.
    Davis SEB; Dehne KA; Rubinos CA; Lau WK; Northam KA
    Neurohospitalist; 2022 Apr; 12(2):276-279. PubMed ID: 35419146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical safety and efficacy of andexanet alfa in animal models.
    Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB
    J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
    Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ
    Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding.
    Korobey MJ; Sadaka F; Javed M; Moynihan M; Alsaei A
    Neurocrit Care; 2021 Feb; 34(1):112-120. PubMed ID: 32430804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Managing the perioperative patient on direct oral anticoagulants.
    Leitch J; van Vlymen J
    Can J Anaesth; 2017 Jun; 64(6):656-672. PubMed ID: 28429198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.
    Siegal D; Lu G; Leeds JM; Karbarz M; Castillo J; Mathur V; Hutchaleelaha A; Sinha U; Kitt M; McClure M; Hollenbach SJ; Curnutte JT; Conley PB; Crowther M
    Blood Adv; 2017 Sep; 1(21):1827-1838. PubMed ID: 29296829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report.
    Flaherty D; Connors JM; Singh S; Sylvester KW; Rimsans J; Cornella L
    A A Pract; 2019 Oct; 13(7):271-273. PubMed ID: 31265446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Andexanet alfa: the best antidote for factor Xa inhibitors?].
    Klok FA; Huisman MV
    Ned Tijdschr Geneeskd; 2019 Jun; 163():. PubMed ID: 31283119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
    Weitz JI
    Semin Respir Crit Care Med; 2017 Feb; 38(1):40-50. PubMed ID: 28208197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
    Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis.
    Shrestha DB; Budhathoki P; Adhikari A; Shrestha S; Khati N; Mir WAY; Joshi T; Shrestha A
    Cureus; 2021 Dec; 13(12):e20632. PubMed ID: 35103198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
    Sheikh-Taha M
    Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US.
    Fanikos J; Goldstein JN; Lovelace B; Beaubrun AC; Blissett RS; Aragão F
    J Med Econ; 2022; 25(1):309-320. PubMed ID: 35168455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.